LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Published:2019-11-21 Issue:22 Volume:3 Page:3661-3673
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Beeharry Neil¹^ORCID,Landrette Sean¹,Gayle Sophia¹,Hernandez Marylens¹,Grotzke Jeff E.¹,Young Peter R.¹,Beckett Paul¹,Zhang Xuan²^ORCID,Carter Bing Z.²,Andreeff Michael³^ORCID,Halene Stephanie⁴,Xu Tian⁵,Rothberg Jonathan¹,Lichenstein Henri¹

Affiliation:

1. AI Therapeutics, Guilford, CT;

2. Department of Leukemia and

3. Department of Leukemia and Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX; and

4. Department of Hematology and

5. Howard Hughes Medical Institute, Department of Genetics, Yale School of Medicine, New Haven, CT

Abstract

Key Points The heat shock protein 90 inhibitor LAM-003 displays potent in vitro and in vivo activity as a single agent and combined with venetoclax. LAM-003 retains antileukemic activity against AML cells rendered resistant to FLT3 kinase inhibitors by mutation or stromal signaling.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/22/3661/1542495/advancesadv2019001068.pdf

Reference68 articles.

1. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias;Carow;Blood,1996

2. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

3. How I treat FLT3-mutated AML;Pratz;Blood,2017

4. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia;Kiyoi;Blood,1999

5. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm;Fröhling;Blood,2002

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy;Critical Reviews in Oncology/Hematology;2024-09

2. CRISPR screening in hematology research: from bulk to single-cell level;Journal of Hematology & Oncology;2023-10-24

3. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells;Blood;2023-09-21

4. NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia;Cell Death Discovery;2023-06-30

5. Phytochemicals and bioactive compounds effective against acute myeloid leukemia: A systematic review;Food Science & Nutrition;2023-05-15